Table 1 Subjects analyzed, mutations,... | American Society of Hematology

Table 1

Subjects analyzed, mutations, and clinical details

Patient	Diagnosis	Mutation	Genomic abnormality	Sex	Age, y	WBCs, ×10⁹/L	Platelets, ×10⁹/L	Karyotype	Disease progression	Death, mo
E7168	CMML	SUZ12 F603L	aUPD 17q	F	80	49	87	46,XX		55
UPN 30	Post-PV MF	SUZ12 D605V	del(17q11.2)	M	64	44	164	Not known	PV at age 57; underwent SCT shortly after progression to MF but relapsed with AML	6
UPN 23	Post-ET MF	SUZ12 I600T NF1 528ΔT	del(17q11.2)	M	54	6	450	46,XY	ET at age 50; SCT at age 60 after evidence of increasing blasts (from 10% to 19%)
E7169	CMML	SUZ12 E610G	None	F	84	50	23	46,XX	AML (43 mo)	43
E1880	aCML	EED G255D	None	M	69	28	46	46,XY		9

Patient	Diagnosis	Mutation	Genomic abnormality	Sex	Age, y	WBCs, ×10⁹/L	Platelets, ×10⁹/L	Karyotype	Disease progression	Death, mo
E7168	CMML	SUZ12 F603L	aUPD 17q	F	80	49	87	46,XX		55
UPN 30	Post-PV MF	SUZ12 D605V	del(17q11.2)	M	64	44	164	Not known	PV at age 57; underwent SCT shortly after progression to MF but relapsed with AML	6
UPN 23	Post-ET MF	SUZ12 I600T NF1 528ΔT	del(17q11.2)	M	54	6	450	46,XY	ET at age 50; SCT at age 60 after evidence of increasing blasts (from 10% to 19%)
E7169	CMML	SUZ12 E610G	None	F	84	50	23	46,XX	AML (43 mo)	43
E1880	aCML	EED G255D	None	M	69	28	46	46,XY		9

Post-PV MF indicates post-polycythemia myelofibrosis; post-ET MF, post-essential thrombocythemia myelofibrosis; aCML, atypical chronic myeloid leukemia; and SCT, stem cell transplantation.